Prospective cohort study of early biosignatures of response to lithium in bipolar-I-disorders: overview of the H2020-funded R-LiNK initiative

Publikationstyp:
Zeitschriftenaufsatz
Metadaten:
Autoren
  • Jan Scott
  • Diego Hidalgo-Mazzei
  • Rebecca Strawbridge
  • Allan Young
  • Matthieu Resche-Rigon
  • Bruno Etain
  • Ole A Andreassen
  • Michael Bauer
  • Djamila Bennabi
  • Andrew M Blamire
  • Fawzi Boumezbeur
  • Paolo Brambilla
  • Nadia Cattane
  • Annamaria Cattaneo
  • Marie Chupin
  • Klara Coello
  • Yann Cointepas
  • Francesc Colom
  • David A Cousins
  • Caroline Dubertret
  • Edouard Duchesnay
  • Adele Ferro
  • Aitana Garcia-Estela
  • Jose Goikolea
  • Antoine Grigis
  • Emmanuel Haffen
  • Margrethe C Hoegh
  • Petter Jakobsen
  • Janos L Kalman
  • Lars V Kessing
  • Farah Klohn-Saghatolislam
  • Trine V Lagerberg
  • Mikael Landen
  • Ute Lewitzka
  • Ashley Lutticke
  • Nicolas Mazer
  • Monica Mazzelli
  • Cristina Mora
  • Thorsten Muller
  • Estanislao Mur-Mila
  • Ketil Joachim Oedegaard
  • Leif Oltedal
  • Erik Palsson
  • Dimitri Papadopoulos Orfanos
  • Sergi Papiol
  • Victor Perez-Sola
  • Andreas Reif
  • Philipp Ritter
  • Roberto Rossi
  • Thomas Schulze
  • Fanny Senner
  • Fiona E Smith
  • Letizia Squarcina
  • Nils Eiel Steen
  • Pete E Thelwall
  • Cristina Varo
  • Eduard Vieta
  • Maj Vinberg
  • Michele Wessa
  • Lars T Westlye
  • Frank Bellivier
Autoren-URL
https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=fis-test-1&SrcAuth=WosAPI&KeyUT=WOS:000487604000001&DestLinkType=FullRecord&DestApp=WOS_CPL
DOI
10.1186/s40345-019-0156-x
Externe Identifier
  • Clarivate Analytics Document Solution ID: JA1UV
  • PubMed Identifier: 31552554
ISSN
2194-7511
Ausgabe der Veröffentlichung
1
Zeitschrift
INTERNATIONAL JOURNAL OF BIPOLAR DISORDERS
Schlüsselwörter
  • Bipolar
  • Precision
  • Personalization
  • Lithium
  • Response
  • Phenotype
  • Digital
  • Actigraphy
  • Omics
  • Neuroimaging
Artikelnummer
ARTN 20
Datum der Veröffentlichung
2019
Status
Published
Titel
Prospective cohort study of early biosignatures of response to lithium in bipolar-I-disorders: overview of the H2020-funded R-LiNK initiative
Sub types
  • Review
Ausgabe der Zeitschrift
7

Datenquelle: Web of Science (Lite)

Andere Metadatenquellen:
Abstract
<jats:title>Abstract</jats:title> <jats:sec> <jats:title>Background</jats:title> <jats:p>Lithium is recommended as a first line treatment for bipolar disorders. However, only 30% of patients show an optimal outcome and variability in lithium response and tolerability is poorly understood. It remains difficult for clinicians to reliably predict which patients will benefit without recourse to a lengthy treatment trial. Greater precision in the early identification of individuals who are likely to respond to lithium is a significant unmet clinical need.</jats:p> </jats:sec> <jats:sec> <jats:title>Structure</jats:title> <jats:p>The H2020-funded Response to Lithium Network (R-LiNK; <jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.r-link.eu.com/">http://www.r-link.eu.com/</jats:ext-link>) will undertake a prospective cohort study of over 300 individuals with bipolar-I-disorder who have agreed to commence a trial of lithium treatment following a recommendation by their treating clinician. The study aims to examine the early prediction of lithium response, non-response and tolerability by combining systematic clinical syndrome subtyping with examination of multi-modal biomarkers (or biosignatures), including omics, neuroimaging, and actigraphy, etc. Individuals will be followed up for 24 months and an independent panel will assess and classify each participants’ response to lithium according to predefined criteria that consider evidence of relapse, recurrence, remission, changes in illness activity or treatment failure (e.g. stopping lithium; new prescriptions of other mood stabilizers) and exposure to lithium. Novel elements of this study include the recruitment of a large, multinational, clinically representative sample specifically for the purpose of studying candidate biomarkers and biosignatures; the application of lithium-7 magnetic resonance imaging to explore the distribution of lithium in the brain; development of a digital phenotype (using actigraphy and ecological momentary assessment) to monitor daily variability in symptoms; and economic modelling of the cost-effectiveness of introducing biomarker tests for the customisation of lithium treatment into clinical practice. Also, study participants with sub-optimal medication adherence will be offered brief interventions (which can be delivered via a clinician or smartphone app) to enhance treatment engagement and to minimize confounding of lithium non-response with non-adherence.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions</jats:title> <jats:p>The paper outlines the rationale, design and methodology of the first study being undertaken by the newly established R-LiNK collaboration and describes how the project may help to refine the clinical response phenotype and could translate into the personalization of lithium treatment.</jats:p> </jats:sec>
Autoren
  • Jan Scott
  • Diego Hidalgo-Mazzei
  • Rebecca Strawbridge
  • Allan Young
  • Matthieu Resche-Rigon
  • Bruno Etain
  • Ole A Andreassen
  • Michael Bauer
  • Djamila Bennabi
  • Andrew M Blamire
  • Fawzi Boumezbeur
  • Paolo Brambilla
  • Nadia Cattane
  • Annamaria Cattaneo
  • Marie Chupin
  • Klara Coello
  • Yann Cointepas
  • Francesc Colom
  • David A Cousins
  • Caroline Dubertret
  • Edouard Duchesnay
  • Adele Ferro
  • Aitana Garcia-Estela
  • Jose Goikolea
  • Antoine Grigis
  • Emmanuel Haffen
  • Margrethe C Høegh
  • Petter Jakobsen
  • Janos L Kalman
  • Lars V Kessing
  • Farah Klohn-Saghatolislam
  • Trine V Lagerberg
  • Mikael Landén
  • Ute Lewitzka
  • Ashley Lutticke
  • Nicolas Mazer
  • Monica Mazzelli
  • Cristina Mora
  • Thorsten Muller
  • Estanislao Mur-Mila
  • Ketil Joachim Oedegaard
  • Leif Oltedal
  • Erik Pålsson
  • Dimitri Papadopoulos Orfanos
  • Sergi Papiol
  • Victor Perez-Sola
  • Andreas Reif
  • Philipp Ritter
  • Roberto Rossi
  • Thomas Schulze
  • Fanny Senner
  • Fiona E Smith
  • Letizia Squarcina
  • Nils Eiel Steen
  • Pete E Thelwall
  • Cristina Varo
  • Eduard Vieta
  • Maj Vinberg
  • Michele Wessa
  • Lars T Westlye
  • Frank Bellivier
DOI
10.1186/s40345-019-0156-x
eISSN
2194-7511
Ausgabe der Veröffentlichung
1
Zeitschrift
International Journal of Bipolar Disorders
Sprache
en
Artikelnummer
20
Online publication date
2019
Datum der Veröffentlichung
2019
Status
Published
Herausgeber
Springer Science and Business Media LLC
Herausgeber URL
http://dx.doi.org/10.1186/s40345-019-0156-x
Datum der Datenerfassung
2020
Titel
Prospective cohort study of early biosignatures of response to lithium in bipolar-I-disorders: overview of the H2020-funded R-LiNK initiative
Ausgabe der Zeitschrift
7

Datenquelle: Crossref

Abstract
<h4>Background</h4>Lithium is recommended as a first line treatment for bipolar disorders. However, only 30% of patients show an optimal outcome and variability in lithium response and tolerability is poorly understood. It remains difficult for clinicians to reliably predict which patients will benefit without recourse to a lengthy treatment trial. Greater precision in the early identification of individuals who are likely to respond to lithium is a significant unmet clinical need.<h4>Structure</h4>The H2020-funded Response to Lithium Network (R-LiNK; http://www.r-link.eu.com/ ) will undertake a prospective cohort study of over 300 individuals with bipolar-I-disorder who have agreed to commence a trial of lithium treatment following a recommendation by their treating clinician. The study aims to examine the early prediction of lithium response, non-response and tolerability by combining systematic clinical syndrome subtyping with examination of multi-modal biomarkers (or biosignatures), including omics, neuroimaging, and actigraphy, etc. Individuals will be followed up for 24 months and an independent panel will assess and classify each participants' response to lithium according to predefined criteria that consider evidence of relapse, recurrence, remission, changes in illness activity or treatment failure (e.g. stopping lithium; new prescriptions of other mood stabilizers) and exposure to lithium. Novel elements of this study include the recruitment of a large, multinational, clinically representative sample specifically for the purpose of studying candidate biomarkers and biosignatures; the application of lithium-7 magnetic resonance imaging to explore the distribution of lithium in the brain; development of a digital phenotype (using actigraphy and ecological momentary assessment) to monitor daily variability in symptoms; and economic modelling of the cost-effectiveness of introducing biomarker tests for the customisation of lithium treatment into clinical practice. Also, study participants with sub-optimal medication adherence will be offered brief interventions (which can be delivered via a clinician or smartphone app) to enhance treatment engagement and to minimize confounding of lithium non-response with non-adherence.<h4>Conclusions</h4>The paper outlines the rationale, design and methodology of the first study being undertaken by the newly established R-LiNK collaboration and describes how the project may help to refine the clinical response phenotype and could translate into the personalization of lithium treatment.
Addresses
  • Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK.
Autoren
  • Jan Scott
  • Diego Hidalgo-Mazzei
  • Rebecca Strawbridge
  • Allan Young
  • Matthieu Resche-Rigon
  • Bruno Etain
  • Ole A Andreassen
  • Michael Bauer
  • Djamila Bennabi
  • Andrew M Blamire
  • Fawzi Boumezbeur
  • Paolo Brambilla
  • Nadia Cattane
  • Annamaria Cattaneo
  • Marie Chupin
  • Klara Coello
  • Yann Cointepas
  • Francesc Colom
  • David A Cousins
  • Caroline Dubertret
  • Edouard Duchesnay
  • Adele Ferro
  • Aitana Garcia-Estela
  • Jose Goikolea
  • Antoine Grigis
  • Emmanuel Haffen
  • Margrethe C Høegh
  • Petter Jakobsen
  • Janos L Kalman
  • Lars V Kessing
  • Farah Klohn-Saghatolislam
  • Trine V Lagerberg
  • Mikael Landén
  • Ute Lewitzka
  • Ashley Lutticke
  • Nicolas Mazer
  • Monica Mazzelli
  • Cristina Mora
  • Thorsten Muller
  • Estanislao Mur-Mila
  • Ketil Joachim Oedegaard
  • Leif Oltedal
  • Erik Pålsson
  • Dimitri Papadopoulos Orfanos
  • Sergi Papiol
  • Victor Perez-Sola
  • Andreas Reif
  • Philipp Ritter
  • Roberto Rossi
  • Thomas Schulze
  • Fanny Senner
  • Fiona E Smith
  • Letizia Squarcina
  • Nils Eiel Steen
  • Pete E Thelwall
  • Cristina Varo
  • Eduard Vieta
  • Maj Vinberg
  • Michele Wessa
  • Lars T Westlye
  • Frank Bellivier
DOI
10.1186/s40345-019-0156-x
eISSN
2194-7511
Externe Identifier
  • PubMed Identifier: 31552554
  • PubMed Central ID: PMC6760458
Funding acknowledgements
  • Medical Research Council: MR/L006642/1
  • H2020 Research and Innovation Program (EU.3.1.1. Understanding health, wellbeing and disease: Grant No 754907): 754907
  • H2020 Research and Innovation Program: 754907
  • National Institute for Health Research (NIHR): NF-SI-0616-10091
Open access
true
ISSN
2194-7511
Ausgabe der Veröffentlichung
1
Zeitschrift
International journal of bipolar disorders
Sprache
eng
Medium
Electronic
Online publication date
2019
Open access status
Open Access
Paginierung
20
Datum der Veröffentlichung
2019
Status
Published
Publisher licence
CC BY
Datum der Datenerfassung
2019
Titel
Prospective cohort study of early biosignatures of response to lithium in bipolar-I-disorders: overview of the H2020-funded R-LiNK initiative.
Sub types
  • review-article
  • Review
  • Journal Article
Ausgabe der Zeitschrift
7

Files

https://journalbipolardisorders.springeropen.com/track/pdf/10.1186/s40345-019-0156-x https://europepmc.org/articles/PMC6760458?pdf=render

Datenquelle: Europe PubMed Central

Abstract
BACKGROUND: Lithium is recommended as a first line treatment for bipolar disorders. However, only 30% of patients show an optimal outcome and variability in lithium response and tolerability is poorly understood. It remains difficult for clinicians to reliably predict which patients will benefit without recourse to a lengthy treatment trial. Greater precision in the early identification of individuals who are likely to respond to lithium is a significant unmet clinical need. STRUCTURE: The H2020-funded Response to Lithium Network (R-LiNK; http://www.r-link.eu.com/ ) will undertake a prospective cohort study of over 300 individuals with bipolar-I-disorder who have agreed to commence a trial of lithium treatment following a recommendation by their treating clinician. The study aims to examine the early prediction of lithium response, non-response and tolerability by combining systematic clinical syndrome subtyping with examination of multi-modal biomarkers (or biosignatures), including omics, neuroimaging, and actigraphy, etc. Individuals will be followed up for 24 months and an independent panel will assess and classify each participants' response to lithium according to predefined criteria that consider evidence of relapse, recurrence, remission, changes in illness activity or treatment failure (e.g. stopping lithium; new prescriptions of other mood stabilizers) and exposure to lithium. Novel elements of this study include the recruitment of a large, multinational, clinically representative sample specifically for the purpose of studying candidate biomarkers and biosignatures; the application of lithium-7 magnetic resonance imaging to explore the distribution of lithium in the brain; development of a digital phenotype (using actigraphy and ecological momentary assessment) to monitor daily variability in symptoms; and economic modelling of the cost-effectiveness of introducing biomarker tests for the customisation of lithium treatment into clinical practice. Also, study participants with sub-optimal medication adherence will be offered brief interventions (which can be delivered via a clinician or smartphone app) to enhance treatment engagement and to minimize confounding of lithium non-response with non-adherence. CONCLUSIONS: The paper outlines the rationale, design and methodology of the first study being undertaken by the newly established R-LiNK collaboration and describes how the project may help to refine the clinical response phenotype and could translate into the personalization of lithium treatment.
Date of acceptance
2019
Autoren
  • Jan Scott
  • Diego Hidalgo-Mazzei
  • Rebecca Strawbridge
  • Allan Young
  • Matthieu Resche-Rigon
  • Bruno Etain
  • Ole A Andreassen
  • Michael Bauer
  • Djamila Bennabi
  • Andrew M Blamire
  • Fawzi Boumezbeur
  • Paolo Brambilla
  • Nadia Cattane
  • Annamaria Cattaneo
  • Marie Chupin
  • Klara Coello
  • Yann Cointepas
  • Francesc Colom
  • David A Cousins
  • Caroline Dubertret
  • Edouard Duchesnay
  • Adele Ferro
  • Aitana Garcia-Estela
  • Jose Goikolea
  • Antoine Grigis
  • Emmanuel Haffen
  • Margrethe C Høegh
  • Petter Jakobsen
  • Janos L Kalman
  • Lars V Kessing
  • Farah Klohn-Saghatolislam
  • Trine V Lagerberg
  • Mikael Landén
  • Ute Lewitzka
  • Ashley Lutticke
  • Nicolas Mazer
  • Monica Mazzelli
  • Cristina Mora
  • Thorsten Muller
  • Estanislao Mur-Mila
  • Ketil Joachim Oedegaard
  • Leif Oltedal
  • Erik Pålsson
  • Dimitri Papadopoulos Orfanos
  • Sergi Papiol
  • Victor Perez-Sola
  • Andreas Reif
  • Philipp Ritter
  • Roberto Rossi
  • Thomas Schulze
  • Fanny Senner
  • Fiona E Smith
  • Letizia Squarcina
  • Nils Eiel Steen
  • Pete E Thelwall
  • Cristina Varo
  • Eduard Vieta
  • Maj Vinberg
  • Michele Wessa
  • Lars T Westlye
  • Frank Bellivier
Autoren-URL
https://www.ncbi.nlm.nih.gov/pubmed/31552554
DOI
10.1186/s40345-019-0156-x
Externe Identifier
  • PubMed Central ID: PMC6760458
Funding acknowledgements
  • Medical Research Council: MR/L006642/1
  • H2020 Research and Innovation Program (EU.3.1.1. Understanding health, wellbeing and disease: Grant No 754907): 754907
ISSN
2194-7511
Ausgabe der Veröffentlichung
1
Zeitschrift
Int J Bipolar Disord
Schlüsselwörter
  • Actigraphy
  • Bipolar
  • Digital
  • Lithium
  • Neuroimaging
  • Omics
  • Personalization
  • Phenotype
  • Precision
  • Response
Sprache
eng
Country
Germany
Paginierung
20
PII
10.1186/s40345-019-0156-x
Datum der Veröffentlichung
2019
Status
Published online
Titel
Prospective cohort study of early biosignatures of response to lithium in bipolar-I-disorders: overview of the H2020-funded R-LiNK initiative.
Sub types
  • Journal Article
  • Review
Ausgabe der Zeitschrift
7

Datenquelle: PubMed

Beziehungen:
Eigentum von

Werkzeuge